Pemetrexed Plus Cisplatin for Brain Metastasis of Advanced Non - Small Cell Lung Cancer (NSCLC)

Lung Cancer Clinical Trial

— GFPC 07-01  

Official title:

A Phase II Trial With Pemetrexed Plus Cisplatin as First Line Chemotherapy for Advanced Non - Small Cell Lung Cancer (NSCLC) Patients With Measurable Asymptomatic Brain Metastasis (GFPC 07-01/METAL).

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00744900
• Other study ID #: GFPC 07-01
• Secondary ID: RB 07.103
• Status: Completed
• Phase: Phase 2
• First received: August 29, 2008
• Last updated: July 24, 2009
• Start date: September 2008

Study information

• Verified date: July 2009
• Source: University Hospital, Brest
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
• Study type: Interventional

Clinical Trial Summary

NSCLC patients often have cerebral metastasis : 10% at diagnosis and 40% during disease management. Neurosurgery is not indicated in the majority of cases because of presence of several lesions in the brain, failure of primary tumor control or presence of extra-cerebral metastasis. Cerebral metastasis lead to death in 30 to 50% of these cases. Management of these patients in this situation is based on supportive care and whole-brain radiotherapy. The place of chemotherapy for patients with good performance status was discussed for a long time and it is now admitted. However, the place of new drugs such as pemetrexed, which is currently used as a second line treatment for NSCLC, needs to be further studied. It is known that pemetrexed when added to cisplatin for treatment of NSCLC provides a similar effectiveness when compared to other drugs associations commonly used in this indication. In addition, Cisplatin with Pemetrexed probably present a better safety profile.

The present study is based upon the hypothesis stipulating that the association cisplatin-pemetrexed will be at least as efficient as the others association currently used for treatment of NSCLC and will present a better safety profile. The primary objective of this study is overall response rate on brain metastasis according to RECIST criteria. Secondary judgment criterias are : Overall response rate, PFS after first-line CDDP plus pemetrexed, safety profile, quality of life, neurological symptoms, overall survival.

The trial will enroll up to 45 patients in this single-arm two-stage sequential phase II study with the possibility of stopping the study early because of lack of efficacy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with cytologically or histologically confirmed NSCLC.

• Patient with brain metastasis not amenable to surgery or radiosurgery with curative intent

• At least one brain measurable lesion using RECIST criteria

• ECOG Performance Status =2

• No prior chemotherapy for this cancer

• Prior surgery is allowed provided there is a relapse or progression after the procedure.

• Adequate organ function including the following: Adequate bone marrow reserve:

absolute neutrophil count (ANC) superior or equal to 1.5 X109/L, platelets superior or equal to 100 X 109/L, and hemoglobin superior or equal to 9 g/dL; Hepatic: bilirubin <1.5 times the upper limit of normal (ULN), alkaline phosphatase (AP), aspartate transaminase (AST) and alanine transaminase (ALT) <3xULN (or <5xULN with liver metastases); Renal: Calculated creatinine clearance (CrCl) superior or equal to 45mL/min based on the standard Cockroft and Gault formula

• Signed informed consent document from the patient

• Patient must be at least 18 years of age.

• Estimated life expectancy of at least 12 weeks.

• Effective contraception (men and women) for and during the 6 months following the end of treatment

Exclusion Criteria:

• Symptomatic brain metastasis

• Have received prior radiotherapy for brain metastasis

• Unable or unwilling to take folic acid, vitamin B12 supplementation or dexamethasone (or equivalent corticosteroid); or any other inability to comply with protocol or study related procedures.

• A prior malignancy other than NSCLC, except carcinoma in situ of the cervix or non-melanoma skin cancer, adequately treated low grade [Gleason score <6] localized prostate cancer, unless that prior malignancy was diagnosed and definitively treated at least 5 years previously with no subsequent evidence of recurrence

• Serious concomitant systemic disorders (for example, active infection or abnormal electrocardiogram (ECG) indicative of cardiac disease) that, in the opinion of the investigator, would compromise the safety of the patient and his/her ability to complete study.

• Inability to discontinue administration of aspirin at a dose >1.3g/day or other non-steroidal anti-inflammatory agents for 2 days before, the day of, and 2 days after the dose of pemetrexed (5 days prior for long-acting agents such as piroxicam).

• Presence of fluid accumulations in third spaces, e.g., ascite or pleural effusion, which can be detected clinically (during physical examination), and which cannot be adequately controlled by drainage or other procedures prior to inclusion in the study.

• Peripheral neuropathy > CTC Grade 2

• Patient compliance or geographic distance precluding adequate follow up.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms
• Small Cell Lung Carcinoma

Intervention

Drug:
• Pemetrexed, cisplatin
Alimta 500mg/m² IV 10 min infusion and Cisplatin 75mg/m² IV 60 min on day 1. Cycle will be repeated each 21 days.Folic acid orally 400µg should begin 5-7days prior to the first dose of pemetrexed and continuing daily until 3 weeks after the last dose of pemetrexed. Vitamin B12 will be administered as a 1000 mg intramuscular injection, approximately one week before Day 1 of cycle 1 and should repeat approximately every 9 weeks Dexamethasone, 4 mg or equivalent, should be taken orally twice per day on the day before, the day of, and the day after each dose of pemetrexed.WBRT will be administered with high energy photons systematically after cycle 6 or in case of stable disease (SD) after cycle 4 or progressive disease (PD) at any time. The dose will be 3Gy by fraction, 1 fraction per day, for 10 days.

Locations

Country	Name	City	State
France	Centre Hôspitalier du Pays d'Aix, Service des Maladies Respiratoires	Aix En Provence
France	CHU d'Angers, Service de Pneumologie	Angers
France	Médecine 4, C.H.G. de la Fontonne Antibes	Antibes
France	CHU brest, institut de cancérologie et d'hématologie	Brest
France	Centre François Baclesse	Caen
France	Centre Hospitalier René Dubos - Pontoise, Service d'Oncologie - Hématologie Clinique	Cergy Pontoise
France	Centre Hospitalier, Service de Pneumologie	Charleville
France	CHI, Service de Pneumologie	Creteil
France	Pneumologie, Centre hôspitalier, DRAGUIGNAN	Draguignan
France	CH GAP	GAP
France	Centre Hospitalier Départemental, Service de Pneumologie,	La Roche Sur Yon
France	Hôpital A. Mignot, Service de Pneumologie	Le Chesnay
France	Hopital de la Croix Rousse	Lyon
France	Centre Hôspitalier, Service de Pneumo-Neuro	Mantes La Jolie
France	Hôpital Sainte Margueritte	Marseilles
France	Serv. de Pneumo-Allergo, CH de Martigues	Martigues
France	Serv. de Pneumo - Hôpital St Antoine	Paris
France	Service Pneumologie, Pavillon 1A, CH de Lyon-Sud	Pierre-benite
France	Hôpital Pontchailloux, Service de Pneumologie.	Rennes
France	CHG, Service de Pneumologie	Roanne
France	CHU de ROUEN, Hôpital Bois Guillaume, Serv. de Pneumo.	Rouen
France	Luc THIBERVILLE	Rouen
France	Institut de Cancérologie de la Loire	Saint-Priest en Jarez Cedex
France	CHU, Service du Pr. Carles	Toulouse
France	Pneumologie, Centre Hospitalier	VILLEFRANCHE sur SAONE

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective of this study is overall response rate on brain metastasis according to RECIST criteria.		After cycles 2, 4 and 6 and every 6 weeks after study drug completion in absence of disease progression.	No
Secondary	Overall response rate, PFS after first-line CDDP plus pemetrexed, safety profile, quality of life, neurological symptoms and overall survival.		After cycles 2, 4 and 6 and every 6 weeks after study drug completion.	No